摘要:
AIM:To elucidate risk factors for survival of elderly acute myeloid leukemia(AML)patients in a real-world practice by observational study.METHODS:We conducted a population-based study in 213 adult and elderly AML patients(127 males and 86 females)in Kagawa Prefecture,Japan.To construct this cohort,we gathered all data for patients diagnosed with AML at 7 hospitals in Kagawa between 2006 and 2010.The primary end point was overall survival(OS)after AML diagnosis.Unadjusted Kaplan-Meier survival plots were used to determine OS in the overall cohort.Multivariate analysis was used to determine the independent adverse prognostic factors for OS,with the covariates of interest including age,gender,race/ethnicity,CCI,education,median income,metropolitan statistical area size and history of myelodysplastic syndrome.RESULTS:The average population of Kagawa during the study period was 992489,and the incidence of AML was 4.26 per 100000 person-years.A total of 197 patients with non-acute promyelocytic leukemia(non-APL)(119 males and 78 females)were also included.The median age of non-APL patients was 70 years(average 67,range 24-95).The 5-year OS rate was 21.1%.Subsequent analysis by age group showed that the survival rate declined with age;the 5-year OS rates of non-APL patients younger than 64 years,65-74 years,and older than 75 years were 41.5%,14.1%,and 8.9%,respectively.Multivariate analysis revealed that unfavorable risk karyotype,older age,poor performance status(PS)(3-4),lack of induction chemotherapy,and antecedent haematological disease were independent prognostic predictors.In the subgroup analysis,we also found that older patients with non-APL had lower complete remission rates and higher early death rates than younger patients,irrespective of PS.However,intensive chemotherapy was a significant predictor for longer survival not only in the patients<75 years of age,but also in those over 75 with PS 0-2.CONCLUSION:Age would contribute considerable life expectancy to indicate induction chemotherapy with eligible dose